Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type

Name: Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type
Start: 2029-12-01

December 1, 2029

Company: PROKIDNEY CORP. (PROK)
Drug: renal
Indication: Chronic Kidney Diseases; Type 2 Diabetes Mellitus

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type — PROK Phase 3 Readout | BioSniper